论文部分内容阅读
头孢特仑酯(cefteram pivoxil,CFTM-PI)由日本富山化学工业株式会社研制开发,属第三代口服头孢菌素酯化物.该药口服吸收后经肠管壁酯酶水解成为有抗菌活性的头孢特仑(CFTM),其抗菌谱广,对肠杆菌科等革兰阴性杆菌具高度抗菌活性;对链球菌属、肺炎球菌等革兰阳性球菌亦具良好抗菌作用;与现有第一、二代口服头孢菌素相比对吲哚阳性变形杆菌、弗劳地枸橼酸杆菌、阴沟肠杆菌等肠杆菌科细菌的抗菌作用增强.对β—内酰胺酶高度稳定,国外已上市取得了满意的疗效,患者耐受性好,不良反应少见.
Cefteram pivoxil (cefteram pivoxil, CFTM-PI) developed by Toyama Chemical Co., Ltd., Japan, is the third generation of oral cephalosporin esterified substance. The drug is orally absorbed by the intestinal wall after esterase hydrolysis has antibacterial activity Cefteram (CFTM), its broad antibacterial spectrum of Enterobacteriaceae Gram-negative bacilli with high antibacterial activity; against Streptococcus, pneumococcus and other Gram-positive cocci also has good antibacterial activity; and the existing first, Second-generation oral cephalosporins compared to indole-positive Proteus, freund Citrobacter, Enterobacter cloacae and other Enterobacteriaceae antibacterial activity increased.For β-lactamase highly stable, has been listed abroad Satisfactory efficacy, patient tolerance, and rare adverse reactions.